Endotis Pharma Intiates Phase IIa Study of First-in-Class Neutralizable Anticoagulant in Open-Heart Surgery
6/22/2011 9:11:04 AM
PARIS--(BUSINESS WIRE)--Endotis Pharma, a world leader in the development of neutralizable anticoagulants, today announced enrolment of the first patients into a Phase IIa study using EP217609 and its specific antidote avidin to manage coagulation during open-heart surgery. EP217609 has been specifically designed to provide surgeons with a safer, more predictable option than the current standard anticoagulant, heparin. Open-heart cardiac surgeries are often associated with potentially serious and costly complications, largely as a result of excessive bleeding caused by the surgery itself and by difficulties in managing the anticoagulation process.